Partners HealthCare raises $171M to invest in startups

Boston-based Partners HealthCare closed $171.1 million in capital to invest in early-stage life sciences companies, the health system announced Nov. 8.

The $171.1 million includes a $105 million commitment from Partners institutions for the Partners Innovation Fund and $66.1 million in outside capital for the Partners Innovation Fund II. The funding programs focus on medical innovations created and developed within the Partners system.

The capital commitments to the Partners Innovation Fund include two $50 million commitments from Brigham and Women's Hospital and Massachusetts General Hospital, both based in Boston. Since its launch in 2008, the Partners Innovation Fund has invested in 32 companies across key industry sectors like therapeutics, diagnostics, health IT and medical devices.

The Partners Innovation Fund II is backed by several pharmaceutical companies, including Astellas Pharma, Eli Lilly and Co., ShangPharma Corp., and Simcere Pharmaceutical Group.

"This collaboration underscores Partners' commitment to promote the commercialization of inventions and discoveries originating from the Partners community and to translate those discoveries into treatments for patients," said Anne Klibanski, MD, chief academic officer of Partners HealthCare.

More articles on health IT:
Vanderbilt researchers question results of recent study on hospital data breaches
Former NIH exec joins Texas A&M University to lead its engineering health program
Tiger Institute Health Alliance HIE joins Sequoia Project to improve interoperability in Missouri

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months